Ebselen clinical trials
Also written SPI-1005 and PZ-51.
How each study uses ebselen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ebselen studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2006 | 1 |
| 2015 | 1 |
| 2017 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 3
Sound Pharmaceuticals, Incorporated (11) · University of Oxford (2) · Brigham and Women's Hospital (1)
Related medicines
As reviewed, each with the page that says it.
- One of Antioxidants source
- One of Neuroprotective Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test ebselen, phase 3 first.
- Dec 2026SPI-1005 for the Treatment of Meniere's Disease (Open Label)Phase 3 · Sound Pharmaceuticals, Incorporated
- Dec 2026SPI-1005 in Adults Receiving Cochlear ImplantPhase 2 · Sound Pharmaceuticals, Incorporated
Studies
Open first, then newest update. How each study uses ebselen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- SPI-1005 in Adults Receiving Cochlear ImplantRecruitingPhase 2Sound Pharmaceuticals, IncorporatedNCT06340633Written as Ebselen
- SPI-1005 Treatment in Moderate COVID-19 PatientsEnrolling by invitationPhase 2Sound Pharmaceuticals, IncorporatedNCT04484025Written as Ebselen
- IMPase in Treatment-resistant DepressionRecruitingPhase 1University of OxfordNCT05117710Written as Ebselen
- SPI-1005 for the Treatment of Meniere's DiseaseCompletedPhase 3Sound Pharmaceuticals, IncorporatedNCT04677972Written as Ebselen
- SPI-1005 for Prevention and Treatment of Tobramycin Induced OtotoxicityCompletedPhase 2Sound Pharmaceuticals, IncorporatedNCT02819856Written as SPI-1005 Ebselen 200mg Capsule x1
- SPI-1005 for the Treatment of Meniere's Disease (Open Label)Active, not recruitingPhase 3Sound Pharmaceuticals, IncorporatedNCT06859788Written as Ebselen
- SPI-1005 Treatment in Severe COVID-19 PatientsCompletedPhase 2Sound Pharmaceuticals, IncorporatedNCT04483973Written as Ebselen
- Study to Evaluate SPI-1005 in Adults With Meniere's DiseaseCompletedPhase 1/2Sound Pharmaceuticals, IncorporatedNCT02603081Written as SPI-1005
- A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing LossWithdrawnPhase 2Sound Pharmaceuticals, IncorporatedNCT02779192Written as SPI-1005 200mg
- SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing LossWithdrawnPhase 2Sound Pharmaceuticals, IncorporatedNCT01451853Written as SPI-1005 Low Dose
- SPI-1005 for the Treatment of Patients With Meniere's DiseaseCompletedPhase 2Sound Pharmaceuticals, IncorporatedNCT03325790Written as 200mg SPI-1005 BID
- Ebselen as an add-on Treatment in Hypo/ManiaCompletedPhase 2University of OxfordNCT03013400Written as Ebselen
- Study to Evaluate the Safety and Pharmacokinetics of SPI-1005CompletedPhase 1Sound Pharmaceuticals, IncorporatedNCT01452607Written as SPI-1005
- Signaling Mechanisms and Vascular Function in Patients With Diabetes MellitusCompletedPhase 2/3Brigham and Women's HospitalNCT00762671Written as Ebselen
As the comparator · 1 — what is tested is compared with ebselen
Codes
What other systems call ebselen · ClinicalTrials.gg INT003168
- MeSH (NLM) C042986ebselenConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 40X2P7DPGHEBSELENConfirmed FDA, NLM, Wikidata
- Wikidata Q5332073ebselenConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65503EbselenOne source FDA
- DrugBank DB12610One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C042986 | ebselen | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 40X2P7DPGH | EBSELEN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5332073 | ebselen | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65503 | Ebselen | One source FDA |
| DrugBank | DB12610 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.